Here are the 10-Q quarterly reports from Klotho Neurosciences, Inc. (KLTO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLTO filings page.
Greenland Mines Ltd reported a much larger quarterly loss as it pivoted into mining. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $13,857,203, compared with $2,116,726 a year earlier, driven by higher general and administrative, professional, and share-based compensation expenses plus a $2,045,253 impairment of biotech intangibles.
Cash and cash equivalents were $10,002,477, with net cash used in operating activities of $4,971,143. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. During the quarter, Greenland Mines completed a forward merger to acquire mineral rights and exploration licenses for the Skaergaard Project, recognizing indefinite-lived mineral intangibles of $48,416,474 and creating a new Mining segment alongside its Biotech operations.
The company raised gross proceeds of about $7,750,000 via a private placement and ended the period with 121,238,660 common shares outstanding. Nasdaq granted an extension until September 14, 2026 for the stock to regain the $1.00 minimum bid price. Subsequent to quarter-end, Greenland Mines agreed to acquire Neo North Star Resources, owner of the Sarfartoq rare earth project, for $35 million, split between $20 million in cash and $15 million in new common shares.
Klotho Neurosciences (KLTO) filed its Q3 2025 10‑Q, reporting continued pre‑revenue operations and a larger year‑to‑date loss alongside improved liquidity from recent financings. The company posted a net loss of $2,895,585 for the quarter and $9,222,798 for the nine months ended September 30, 2025. Cash and cash equivalents were $7,348,034 at quarter‑end, supported by $11,894,683 of net cash from financing activities year‑to‑date.
Management recorded higher research and development spending and interest expense, while share‑based compensation decreased versus last year. During 2025, holders exercised approximately 11.0 million warrants for $11.4 million in gross proceeds, and the company set up an at‑the‑market program of up to $50,000,000 (initial sales included 5,000 shares for $5,300; subsequent settlements totaled about $1.076 million). Shares outstanding were 72,536,722 as of November 13, 2025.
The filing notes substantial doubt about the ability to continue as a going concern without additional funding and discloses a Nasdaq minimum bid price deficiency with a compliance window until March 18, 2026. Internal controls remain weak due to limited accounting resources, though management believes the financial statements are fairly stated.